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Abstract The treatment of hypertension in children and
adolescents has been markedly changed in recent years by
several factors, including the publication of new consensus
recommendations, the obesity epidemic, and the increased
availability of information on efficacy and safety of
antihypertensive medications in the young. In this review
we present an updated approach to the outpatient manage-
ment of hypertension in the child or adolescent, utilizing
representative cases to illustrate important principles as well
as possible controversies.
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Metabolicsyndrome
Definition, classification and identification
of hypertension
In adults, the definition of hypertension is based upon
outcomes such as myocardial infarction and stroke; large-
scale population studies have demonstrated that the
incidence of these events increases in a linear fashion,
beginning with blood pressures >120/80 mmHg [1]. Since
such outcomes are exceedingly rare in children and
adolescents, the definition of elevated blood pressure in
the young is a statistical one, derived from databases of
blood pressures obtained in healthy children. The most
recent classification scheme for blood pressure in children
and adolescents is that recommended by the United States
National High Blood Pressure Education Program
(NHBPEP) Working Group in 2004 (Table 1)[ 2]. Although
this scheme has its flaws (for example, reliance on one
blood pressure measurement per subject, obtained with a
mercury sphygmomanometer), it has been generally
adopted worldwide.
Current consensus recommendations from the NHBPEP
state that blood pressure be measured in all children and
adolescents ≥3 years old at all medical encounters, as well
as in selected children <3 years old at risk for hypertension
[2]. Since blood pressure is known to be quite labile in
childhood, and since there is a high prevalence of the
“white coat” effect in the young, it is recommended that
elevated blood pressure measurements be repeated before a
child is identified as hypertensive and a diagnostic
evaluation is undertaken. The NHBPEP Working Group
definition of hypertension is actually based on the child’s
having an elevated blood pressure documented on three
occasions. The full list of normative blood pressure (BP)
values is available in the Fourth Report [2], which can be
obtained free on-line at http://www.nhlbi.nih.gov/health/
prof/heart/hbp/hbp_ped.htm. These recommendations also
include guidance on how soon repeat blood pressures
should be obtained after it has been confirmed that a child
or adolescent has an elevated BP, and when and how soon a
diagnostic workup should be initiated (Table 2).
One potential flaw of using office blood pressure
measurements alone is the possibility of mis-identifying
patients as having hypertension when, in fact, their blood
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e-mail: joseph.flynn@seattlechildrens.orgpressures are normal. This phenomenon, known as white-
coat hypertension, may be seen in up to 60% of children
referred for the evaluation of elevated blood pressure [3]. It
is important to identify white-coat hypertension, since it
does not appear to be associated with the development of
hypertensive target-organ damage, meaning that further
evaluation can be avoided. The opposite phenomenon,
termed masked hypertension, is seen when office blood
pressures are normal but the child or adolescent is actually
hypertensive. Masked hypertension is especially important
to identify in children with underlying renal disease, in
whom elevated blood pressures may contribute to progres-
sion. Both of these phenomena can be detected by
ambulatory blood pressure monitoring [3], a technique that
is finding greater application in the evaluation of children
with elevated blood pressure. We feel that ambulatory
blood pressure monitoring (ABPM) should be used to
confirm hypertension in otherwise healthy children and
adolescents, and to confirm normotension in those with
chronic kidney disease (CKD), as part of the initial
evaluation of such patients.
Guiding principles of hypertension management
After the diagnosis of hypertension has been confirmed and
the underlying etiology (if any) identified, an individualized
treatment regimen should be initiated. Most authorities
recommend that this include non-pharmacologic measures
for all patients, with addition of antihypertensive medica-
tions in a selected group of children (Table 3). Medications
are not recommended for all patients, since there are no
long-term pediatric data on their benefits or adverse effects
on growth and development. Although recent legislative
initiatives in the USA and Europe have produced, and will
continue to produce, substantial data on the short-term
efficacy and tolerability of antihypertensive agents in
children and adolescents [4], it is unlikely that studies of
sufficient duration to answer the long-term questions will
ever be conducted in the young.
Non-pharmacologic approaches to hypertension general-
ly consist of dietary changes, increased physical activity
and weight loss in the obese. Although it is difficult to
apply each of these measures successfully in practice,
evidence supporting their efficacy in children and adoles-
cents exists, so they remain a cornerstone of recent
consensus recommendations [2]. Furthermore, studies con-
ducted in adults have demonstrated that successful lifestyle
modification may enhance the efficacy of antihypertensive
drug therapy [1]. While a detailed review of these
approaches is beyond the scope of this article, we will
review pertinent aspects of non-pharmacologic manage-
ment in the case discussions below.
Antihypertensive drug prescribing in children and
adolescents should generally begin with the physician’s
choosing an agent appropriate to the underlying etiology
of the patient’s hypertension. An example of this is the
use of diuretics in acute glomerulonephritis or other forms
of volume-overload hypertension. Other specific exam-
ples of appropriate initial drug choice will be provided in
t h ec a s ed i s c u s s i o n s .C o n troversy does remain with
respect to choice of initial agent when there is no specific
underlying etiology of hypertension identified. In adults,
a thiazide diuretic is usually chosen, based upon evidence
of the superiority of this class in reducing cardiovascular
Table 2 Recommended frequency for repeat blood pressure measure-
ments in children and adolescents ≤17 years of age (adapted from [2])
BP level
a Frequency of BP measurement
Normal Recheck at next regularly scheduled physical
examination
Pre-
hypertensive
Recheck in 6 months
Stage 1
hypertension
Recheck in 1–2 weeks or sooner if the patient
is symptomatic; if BP is persistently elevated on
two additional occasions, evaluate or refer to
source of care within 1 month
Stage 2
hypertension
Evaluate or refer to source of care within 1 week or
immediately if the patient is symptomatic
aBased upon classification scheme in Table 1
Table 1 Classification of elevated blood pressure in children and
adolescents ≤17 years of age (adapted from [2])
Classification Blood pressure value
Normal <90th percentile
a
Pre-hypertensive ≥90th and <95th percentiles
or ≥120/80 mmHg in adolescents
Hypertensive ≥95th percentile
Stage 1 hypertension 95th to 99th percentile +5 mmHg
Stage 2 hypertension ≥99th percentile +5 mmHg
aSee tables published in [2] (Fourth Report)
Table 3 Indications for antihypertensive medications in hypertensive
children and adolescents (adapted from [2])
Indications
• Stage 2 hypertension
• Symptomatic hypertension
• Secondary hypertension
• Hypertensive target-organ damage
• Diabetes (types 1 and 2)
• Persistent hypertension despite non-pharmacologic measures
1940 Pediatr Nephrol (2009) 24:1939–1949morbidity and mortality in large-scale trials such as the
Antihypertensive and Lipid-Lowering Treatment to Pre-
vent Heart Attack Trial (ALLHAT), in which multiple
classes of antihypertensive agents were compared [5].
Given the lack of comparable studies in the young, the
choice of initial agent in children with primary hyperten-
s i o nr e m a i n su pt ot h ei n d i v i dual practitioner. No matter
what agent is chosen, it is advisable from several stand-
points to prescribe only those agents that have established
pediatric indications and/or labeling information [2].
Fortunately, the number of such agents has greatly
increased over the past 10 years, and detailed information
on the efficacy of specific agents in hypertensive children
and adolescents is now available [4]. Recommended
doses for drugs used in outpatient treatment of hyperten-
sion in children and adolescents can be found in Table 4.
Once an initial antihypertensive agent has been chosen, a
stepped-care approach (Fig. 1)[ 4] should be followed.
Stepped-care allows for the individualization of therapy
according to the needs of the patient and also facilitates
detection of adverse effects as drug doses are increased or
new agents added. It has been endorsed by the last three
pediatric working groups of the NHBPEP [2]a sa n
appropriate approach to the use of antihypertensive drugs
in children and adolescents. After initiation of drug therapy,
follow-up visits should be scheduled frequently (every 2–
4 weeks) until blood pressure control has been achieved,
and then less frequently (every 3–4 months) thereafter.
Home blood pressure monitoring and assessment for
medication side-effects are important components of treat-
ment and should be reviewed at each follow-up visit.
Periodic reassessment for hypertensive target-organ damage
and laboratory monitoring, as appropriate, should also be
incorporated into each child’s treatment plan.
Case presentations
In the remainder of the article we have taken a case-based
approach to the discussion of hypertension management.
Instead of a straightforward discussion of lifestyle changes,
medication choice, etc., we instead present three hypothet-
ical patients that are similar to many children we have
evaluated and treated for hypertension. We feel that this
format lends itself to a more realistic discussion of key
management issues that overlaps with other aspects such as
diagnosis and prognosis.
The hypertensive athlete
S. is a 14-year-old soccer player referred for evaluation of
elevated blood pressure detected at a pre-sports participa-
tion screening at her school. Blood pressures obtained at
the screening ranged from 137–149/75–80 mmHg. She is at
the 50th percentile for height and weight and has no other
chronic health problems or abnormal physical examination
findings. Because of the elevated BPs, her soccer coach will
not allow her to participate on the team. She and her family
have asked you to write a letter allowing her to play
without restrictions.
Over 30 million children and adolescents in the USA par-
ticipate in organized team sports [6]. When the young athlete
is found to be hypertensive, several issues arise regarding the
clinical evaluation, sports eligibility, and best therapy.
The clinical history of the hypertensive athlete should
include questions about the use of performance-enhancing
substances, such as anabolic steroids, herbs, supplements,
caffeine-containing energy drinks, and stimulants, as many
of these can elevate blood pressure. The prevalence of
anabolic steroid use among high-school athletes is as high
as 3–7%, and approximately 10% of anabolic steroid users
are teenagers [6, 7]. Findings on physical examination that
should increase the suspicion for steroid use include
increased muscle mass, acne, and striae; gynecomastia,
and testicular atrophy in males; and facial hair, deep
voice, baldness, and breast atrophy in females [6]. Athletes
should be questioned about the use of non-steroidal anti-
inflammatory drugs, and females about oral contraceptives,
as both can raise blood pressure [8, 9]. Twenty-four hour
ABPM should be strongly considered in order to exclude
white-coat hypertension in athletes with elevated office
blood pressure. The evaluation of all athletes with con-
firmed hypertension should include analyses for levels of
blood urea nitrogen (BUN), creatinine, and electrolytes;
urinalysis, renal ultrasound, fasting lipid profile, and echo-
cardiogram [2]. Fit athletes with no identifiable risk factors
for hypertension on current history, past medical history, or
family history should have further investigation for reno-
vascular hypertension and other secondary causes of
hypertension, according to the recommendations of the
NHBPEP Working Group [2].
The current role of exercise stress testing in the
evaluation of the hypertensive youth is not well defined.
While exercise testing can be used to test the functional
capacity for athletic activities, the American College of
Sports Medicine does not recommend routine exercise
testing of the hypertensive athlete [10–12]. Furthermore,
neither adult nor pediatric expert panels identify exercise
stress testing as part of the routine evaluation of individuals
in whom hypertension is the only cardiovascular abnor-
mality [2, 10, 13].
Providers sometimes restrict hypertensive youth from
athletics for fear that elevated BP values reached during
exercise will lead to morbid events such as stroke or
myocardial ischemia. The concern stems, in part, from the
experience with vigorous exercise in hypertensive adults
Pediatr Nephrol (2009) 24:1939–1949 1941T
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1942 Pediatr Nephrol (2009) 24:1939–1949[11]. Blood pressure response to dynamic exercise differs
from the response to static exercise. Normally, dynamic
exercise raises systolic BP due to increased cardiac output.
Conversely, diastolic BP remains unchanged or decreases
due to decreased peripheral vascular resistance. During static
exercise, both systolic and diastolic pressures rise and often
to a higher level [13]. In comparison to normotensive
subjects, hypertensive children and adults can have an
exaggerated increase in systolic BP and increased diastolic
pressure during dynamic exercise testing [12, 14]. In adults
with atherosclerotic disease, the exaggerated blood pressure
response to exercise can be associated with mild systolic
dysfunctionandispredictiveofincidentcardiovascularevents
[15, 16]. Furthermore, sudden death due to vigorous exertion
has been reported in hypertensive adults over 35 years old
who have atherosclerotic coronary artery disease [17].
However, the experience in hypertensive youth differs
from that of adults. To date, sudden death due to exercise
has not been reported in either overweight or hypertensive
youth in the absence of other cardiovascular abnormalities,
such as hypertrophic cardiomyopathy [18, 19]. Further-
more, studies of exercise stress testing in children and
adolescents with hypertension, although limited in number,
show no evidence of cardiovascular complications related
to either dynamic or isometric exercise [14, 19].
The issue of sports participation in hypertensive children
and adolescents has been considered by several expert
panels, including the 36th Bethesda Conference, the
NHBPEP Working Group, and the American Academy of
Pediatrics Committee on Sports Medicine and Fitness.
Competitive sports participation and highly static sports
should be limited only in the presence of uncontrolled
stage 2 hypertension or target-organ damage [2, 12, 20].
Cardiovascular conditioning less rigorous than competitive
sports activity may not need to be restricted, and sports
eligibility can resume once blood pressure is adequately
controlled [12, 20]. Alpert has made the case for not
limiting competitive sports activity in hypertensive youth,
given the lack of evidence of any risk and given the
importance, both psychologically and physically, of sports
participation [19]. A generalized conditioning program
should also be implemented for hypertensive children and
adolescents participating in competitive sports [21].
Physicians are sometimes hesitant to allow hypertensive
athletes to continue weight lifting. The concern comes from
the extreme elevations in blood pressure (as high as 480/
350 mmHg) and rare cases of subarachnoid hemorrhage
reported in a small number of elite power lifters [22].
However, randomized, controlled trials in adults show that
progressive resistance training can lower resting blood
pressure, and no harmful effects of resistance training have
been demonstrated in hypertensive children and adolescents
[11, 16, 19]. The American College of Sports Medicine
recommends that athletes with hypertension establish a
training program that includes both dynamic and resistance
exercise [11]. Similarly, the NHBPEP Working Group has
recognized the potential benefit of both aerobic exercise
and resistance training, with the notable exception of power
lifting [2].
Therapeutic lifestyle modification is essential for any
child or adolescent with hypertension and should include
regular physical activity, a diet limited in sodium but rich in
fresh fruits and vegetables, fiber, and low-fat dairy
products, and the avoidance of excess weight gain [2].
Regular exercise is beneficial for those suffering both
obesity and hypertension, and weight loss programs that
incorporate regular exercise are more effective than those
using nutritional management alone [21].
In addition to the implementation of therapeutic lifestyle
changes, some athletes will require pharmacologic therapy
for hypertension management. The choice of medication
should take into account side-effect profiles of particular
importance to athletes [16]. Furthermore, physicians and
athletes should be aware that the use of diuretics and beta-
blockers has been banned by college sport and Olympic
governing bodies [20]. In general, diuretics should be
avoided in athletes, because of the risk of dehydration, heat
illness, and electrolyte abnormalities. Beta-blockers should
be avoided, due to the potential for reduction in maximal
exercise capacity [16]. Angiotensin-converting enzyme
inhibitors, angiotensin-II receptor blockers, and calcium
channel blockers have low side-effect profiles, do not affect
exercisetolerance,andarelistedasacceptabledrugclassesfor
use in hypertensive children by the Working Group [2, 16].
Angiotensin-converting enzyme inhibitors and angiotensin-II
receptor blockers are contraindicated in pregnancy, due to
the risk of fetal damage, which has been reported even after
Fig. 1 Stepped-care approach to antihypertensive therapy
Pediatr Nephrol (2009) 24:1939–1949 1943exposure during the first trimester [23, 24]. Female athletes
of child-bearing age treated with these agents should,
therefore,becounseledtouse contraceptionifsexuallyactive.
Hypertension in chronic kidney disease
A. is a 6-year-old boy with autosomal dominant polycystic
kidney disease. He was diagnosed at birth, due to the
detection of bilateral flank masses on his initial physical
examination in the newborns’ nursery. Recently, he has
been noted to have intermittently elevated blood pressures
during his follow-up visits to your office, with some
readings as high as 130/78 mmHg. He has stage II CKD,
with an estimated glomerular filtration rate (GFR) calcu-
lated by the Schwartz formula of 65 ml/min per 1.73 m
2.
Current medications include sodium bicarbonate, albuterol
for asthma, and multivitamins.
Scope of the problem
Children with CKD are frequently hypertensive. The 2006
annual report of the North American Pediatric Renal Trials
and Collaborative Studies (NAPRTCS) showed that 39.3%
of children enrolled in the chronic renal insufficiency
registry were taking antihypertensive medications [25].
The prevalence of hypertension is especially prominent in
children with CKD due to polycystic kidney disease (83%)
and glomerulonephritis (71%) [26]. Most recently, a
preliminary analysis of 227 children enrolled in the Chronic
Kidney Disease in Children (CKiD) study, an ongoing
prospective, multi-center observational study of North
American children with CKD, showed that 56% were on
antihypertensive therapy and that the prevalence of hyper-
tension increased with decreasing GFR [27]. Furthermore,
studies of ambulatory blood pressure monitoring in children
with CKD demonstrate a high prevalence of nocturnal
hypertension [28]. The high prevalence of hypertension in
children with CKD has significant implications, given the
potential impact on cardiovascular outcomes and progres-
sion of kidney disease.
Hypertension and cardiovascular risk
Cardiovascular disease is the most common cause of death
in adults with CKD [29]. The National Kidney Foundation
(NKF) Task Force on Cardiovascular Disease and the NKF-
Kidney Disease Outcomes Quality Initiative (K/DOQI)
Work Group on Hypertension and Antihypertensive Agents
in Chronic Kidney Disease identified management of
hypertension as essential to the decreasing of cardiovascu-
lar mortality in adults with chronic kidney disease [29–31].
Recently, it has become apparent that children with CKD
are also at increased cardiovascular risk. Analyses of the
US Renal Data Systems database showed that children with
end-stage renal disease (ESRD) have a 1,000 fold higher
cardiac death rate than the age-matched general population,
and cardiac death accounted for 38% of total deaths in
children on dialysis [32, 33]. Moreover, studies show that
cardiovascular abnormalities are common in children with
CKD, even prior to the development of end-stage kidney
disease. Left ventricular hypertrophy (LVH) and increased
carotid intima media thickness (IMT), early surrogate
markers for cardiomyopathy and atherosclerosis, respec-
tively, are common in cross-sectional studies of children
with stage 2 to stage 4 CKD [30, 34]. The role of
hypertension in the development of LVH and increased
carotid IMT has been extensively reviewed in a previous
Educational Feature highlighting the cardiovascular com-
plications of CKD in children [35]. While there have been
no longitudinal studies of the effect of treatment of
hypertension on cardiovascular outcomes in children with
CKD, it is likely that appropriate treatment of hypertension
would ameliorate, in part, the high risk of cardiovascular
disease in individuals with CKD from a young age.
Hypertension and progression of CKD
The NKF Work Group on Hypertension and Antihyper-
tensive Agents in Chronic Kidney Disease defined the
slowing of the progression of CKD as a principal goal of
antihypertensive therapy in CKD [31]. The Modification
of Diet and Renal Disease (MDRD) study demonstrated
that adults with proteinuria had a slower rate of progres-
sion of CKD when target mean arterial blood pressure was
92 mmHg than when it was 107 mmHg. The effect of
more vigorous blood pressure control was most pro-
nounced in patients with proteinuria >3 g/day, and there
was no apparent benefit in adults with <1 g/day protein-
uria [36]. A recent analysis of the NAPRTCS chronic renal
insufficiency database suggests that hypertension plays a
role in the progression of CKD in children as well. In that
analysis, Cox proportional hazards modeling identified
systolic hypertension as an independent predictor of CKD
progression [37].
While the above data are convincing, prospectively
generated data are needed if we are to understand more
clearly the role that hypertension plays in progression of
CKD in children and adolescents. The previously men-
tioned CKiD study [27] includes prospective casual and
ambulatory blood pressure measurement as well as assess-
ment of cardiac structure and function by echocardiogra-
phy, all in conjunction with precise measurement of GFR
by iohexol clearance [27, 30]. This study should answer
1944 Pediatr Nephrol (2009) 24:1939–1949many questions related to the role of blood pressure in
progression of CKD in children.
Treatment of hypertension in CKD patients
Many studies of adults with CKD demonstrate that anti-
hypertensive regimens that include angiotensin-converting
enzyme (ACE) inhibitors or angiotensin receptor blockers
(ARBs) are more effective than regimens based on other
classes of drugs in slowing progression of CKD, partic-
ularly in patients with proteinuria [38]. Some of this
benefit may be due to other effects of these agents, such as
reduction of glomerular fibrosis. Consensus guidelines
recommend that adults with CKD should have a goal
blood pressure <130/80 mmHg and that most adults with
CKD should receive an ACE inhibitor or ARB [1, 31].
Whether ACE inhibition and level of blood pressure
control affect progression of CKD in children is being
prospectively evaluated by the Effect of Strict Blood
Pressure Control and ACE Inhibition on Progression of
CRF in Pediatric Patients (ESCAPE) trial, a multi-center,
prospective trial being conducted in Europe. Patients with
G F R sb e t w e e n1 1m l / m i np e r1 . 7 3m
2 body surface area
a n d8 0m l / m i np e r1 . 7 3m
2 body surface area are
randomly allocated to conventional or intensified blood
pressure management with ramipril, aiming for the 50th to
95th percentile or below the 50th percentile, respectively,
for 24 h mean arterial pressure [39]. Long-term follow-up
of the ESCAPE cohort should help determine the effects
of ACE inhibition in children with CKD. Published
experience with ARB therapy in children with CKD is
more limited, although single-center data suggest that
losartan is well tolerated and confers sustained antihyper-
tensive and renoprotective effects [40].
Combination therapy with ACE inhibition and ARB may
be more beneficial than either class of medication given
alone, although previous studies have been limited by the
use of submaximal dosing of both the combination ACE
inhibitor–ARB and the comparison single drug [38, 41].
Experience with the use of combination therapy with ACE
inhibition and ARB in children with CKD is limited. Small
single-center reports suggest an additive antiproteinuric
effect, but concern has been raised regarding an increased
risk of significant hyperkalemia [42, 43]. Multi-center,
prospective trials comparing ACE inhibition alone with
combined therapy in children with CKD are needed to
establish the safety and efficacy of combined therapy.
Because fluid retention is a common cause of hyperten-
sion in CKD, diuretics are required in many patients to
achieve target blood pressures. Thiazide diuretics are
effective in lowering blood pressure and decrease cardio-
vascular risk in adults. Since thiazides are less effective at
low levels of GFR, loop diuretics are preferred for patients
with a GFR <30 ml/min per 1.73 m
2 [31].
Recently, the role of aldosterone antagonism has received
significant attention in the treatment of hypertensive patients
with CKD. Aldosterone receptor antagonists have been shown
to have beneficial effects on cardiac fibrosis and may also
further ameliorate proteinuria in CKD when used in combina-
tion with an ACE inhibitor or ARB [44]. To date, only one
study of children treated with aldosterone blockade has been
published: a small case series of patients with Alport’s
syndrome in whom addition of spironolactone to an ACE
inhibitor or ACE inhibitor + ARB resulted in a further
reduction in proteinuria without significant adverse effects
[45]. This strategy will clearly need further studies to establish
its role in the treatment of hypertensive children with CKD.
StudiesofadultswithCKDshowthatbothdihydropyridine
calcium channel blockers (CCBs; i.e., amlodipine, nifedipine,
felodipine) and non-dihydropyridine CCBs (diltiazem, verap-
amil) are effective in lowering blood pressure. Non-dihydro-
pyridine CCBs have the additional advantage of decreasing
proteinuria and preserving renal function, whereas dihydro-
pyridine CCBs do not have this effect, possibly because of a
greater loss of renal autoregulation with dihydropyridines
[46]. When used in combination with ACE inhibition,
dihydropyridine CCBs do not detract from the renoprotective
effects of renin–angiotensin blockade, but some authors
recommend the avoidance of these agents as monotherapy
in proteinuric renal disease [46]. Because there is little
experience with non-dihydropyridine CCBs in children, the
role of these potentially renoprotective agents will need to be
determined in prospective, controlled trials before their
routine use in children with CKD can be advocated.
The NHBPEP Working Group recommended that chil-
dren with chronic renal disease have a target blood pressure
<90th percentile for age, gender, and height and that ACE
inhibitors or ARBs should be used preferentially in children
with proteinuric renal disease [2]. A recent survey of North
American pediatric nephrologists confirmed that the vast
majority do use ACE inhibitors for first-line therapy of
hypertension in children with proteinuric kidney disease
[47]. However, preliminary analysis of the CKiD cohort
study found that many children with elevated blood pressure,
defined as blood pressure >90th percentile, were not on
antihypertensive therapy, despite the NHBPEP Working
Group recommendations [27]. Future studies of antihyper-
tensive regimens in children with CKD will help guide best
practice and, hopefully, improve long-term outcomes.
The obese adolescent with metabolic syndrome
J. is a 17-year-old girl referred by the obesity clinic for
evaluation of elevated blood pressures. In addition to blood
pressure readings of 135–147/70–82 mmHg, physical
Pediatr Nephrol (2009) 24:1939–1949 1945examination findings include height >95th percentile, body
mass index (BMI) 47 kg/m
2, acanthosis nigricans and striae
on the proximal extremities and abdomen. Her regular
exercise is limited to gymnastics class twice per week
(30 min per session), and her diet includes many fast-food
meals and at least four servings of soda daily. Her mother
is also obese and has type 2 diabetes; her paternal
grandfather died at age 50 years from a myocardial
infarction. Laboratory evaluation reveals a fasting glucose
concentration of 110 mg/dl, fasting insulin 50 μU/ml, total
cholesterol 185 mg/dl, high-density lipoprotein (HDL)
cholesterol 32 mg/dl, low-density lipoprotein (LDL) cho-
lesterol 153 mg/dl and triglycerides 262 mg/dl.
Obesity has reached epidemic proportions among chil-
dren and adolescents in the USA [48], and its prevalence
appears to be increasing in other countries as well [49]. It
is, therefore, not surprising that complications of obesity,
such as elevated blood pressure, are becoming more
common. In the Houston public schools, for example, a
recent screening study demonstrated that up to 5% of
students had elevated blood pressure [50], which was much
greater than the traditional estimated prevalence of 1–2%
[51]. Persistently elevated blood pressure was present in up
to 11% of those whose BMI was ≥95th percentile for age
and gender.
While the pathogenesis of hypertension in the obese
is complex and not fully understood, two hormonal
abnormalities are likely involved: hyperinsulinemia, a
consequence of peripheral insulin resistance (primarily in
the skeletal muscle), and hyperleptinemia, a consequence of
the increased mass of adipose tissue. Hyperinsulinemia
contributes to the development of hypertension by at
least three proposed mechanisms: altered renal sodium
handling, increased vascular resistance, and increased
activity of the sympathetic nervous system (SNS) [52,
53]. Further activation of the SNS is caused by the
increased levels of leptin, circulating levels of which have
been correlated to blood pressure [54]. Activation of the
SNS has been implicated in clinical studies of obese
children and may explain the predominance of isolated
systolic hypertension in this group [55].
Hypertension is a defining characteristic of the metabolic
syndrome (MS), a constellation of abnormal clinical and
laboratory findings, including central obesity, insulin
resistance and dyslipidemia. The MS is associated with
the development of atherosclerosis and is a strong inde-
pendent predictor of cardiovascular events in hypertensive
adults [56]. At present, there is no consensus on how to
define the MS in children and adolescents, nor is there
consensus on whether the MS in the young should be
viewed primarily as a precursor to type 2 diabetes, or as a
predictor of future cardiovascular disease [57]. At least one
group of investigators has recently demonstrated that compo-
nents of the MS are strongly associated with left ventricular
hypertrophy and other target-organ effects of hypertension
[58], which would be consistent with data from studies of
adults. Given this, the threshold for initiating treatment with
antihypertensive medications should probably be lower in
children and adolescents with the MS than in non-obese
patients with primary hypertension.
Before the patient proceeds to medications, however,
lifestyle modifications should be implemented. Although
success may be difficult to achieve, the benefits have been
well documented in the literature. Two recent studies have
demonstrated that short-term diet and exercise can result in
weight loss, reduced blood pressure, and improvements in
the abnormal laboratory findings associated with the MS in
overweight children and adolescents [59, 60]. Furthermore,
exercise was proven to be more beneficial than metformin
in preventing the development of frank type 2 diabetes in
high risk adults [61]. These studies support the recommen-
dation made by the NHBPEP Working Group that
therapeutic lifestyle changes should be considered primary
therapy for obesity-related hypertension in children and
adolescents.
Pharmacologic management of hypertension in the MS
has two unique aspects to consider: first, the cardiovascular
effects of insulin-sensitizing medications, and second, the
effects of some classes of antihypertensive agents on insulin
sensitivity [62]. Metformin, thiazolidinedione peroxisome
proliferator-activated receptor-γ (PPAR-γ) agonists and the
glucose oxidase inhibitor acarbose have all been shown to
have modest blood pressure lowering effects in clinical
trials in adults, but this effect should be considered
adjunctive to other antihypertensive therapies.
The tendency of diuretics and beta-adrenergic blockers
to affect glucose metabolism is well-known and needs to be
considered when the physician is choosing an antihyper-
tensive agent for obese children with signs of the MS [62].
The combination of these two drug classes is felt to have
significant diabetogenic potential [63] and should probably
be avoided as initial therapy in this patient population. This
stands in contrast to non-obese patients with primary
hypertension, in whom diuretics and beta-adrenergic
blockers would be appropriate as first-line therapy, unless
a specific contraindication, such as severe asthma, was
present. These drug classes do have a role in patients with
the MS, however, usually as second- or third-line agents
when drugs from other classes are not sufficient to achieve
target blood pressure [4]. On the other hand, CCBs, ACE
inhibitors, ARBs and alpha-adrenergic blockers have no
detrimental effects on glucose metabolism and are accept-
able for use as initial agents in obese patients with the
MS—just as they would in non-obese hypertensive patients.
The hypertensive child or adolescent with the MS also
illustrates another important point in the therapy of
1946 Pediatr Nephrol (2009) 24:1939–1949hypertension, namely the need for other cardiovascular risk
factors to monitor on an ongoing basis during treatment.
Screening for dyslipidemia and impaired glucose tolerance
should be performed on a regular basis, not only during the
initial evaluation as recommended by the NHBPEP
Working Group [2], but probably at least annually or
semi-annually. Similar screening should also be included in
the treatment of non-obese patients with primary hyperten-
sion, although perhaps not as often as for obese patients
with the MS. While early exposure to the multiple
cardiovascular risk factors present in the MS clearly
increases the risk of early development of atherosclerosis
[64], the role of imaging in screening for early signs of
atherosclerosis in the young remains to be determined [65].
However, given the increasing evidence that the MS is a
precursor of adult cardiovascular disease [57], vigilance and
early intervention are essential in order to optimize long-
term outcomes for these patients.
Conclusions
The most recent NHBPEP Working Group guidelines,
published in 2004, provide comprehensive recommenda-
tions regarding the evaluation, diagnosis, and therapy of
children and adolescents with elevated blood pressure [2].
Persistently elevated blood pressures are required for the
diagnosis of hypertension, so that the physician may avoid
an incorrect diagnosis in a child with white-coat hyperten-
sion. Ambulatory blood pressure monitoring is more
reliable than clinic blood pressure measurements in the
evaluation for white-coat hypertension; therefore, confir-
mation of hypertension by ambulatory monitoring should
be strongly considered prior to the initiation of pharmaco-
logic therapy. Non-pharmacologic therapeutic life-style
modifications should be instituted in all hypertensive
patients. When indicated, antihypertensive medication
should generally begin with a single agent appropriate to
the underlying pathophysiology of the patient’s hyperten-
sion [4]. Recent legislative initiatives have resulted in a
significant increase in antihypertensive medications ap-
proved for use in children. However, there have been no
comparative studies of efficacy of antihypertensive medi-
cations in childhood hypertension to guide pharmacologic
therapy. The diagnostic evaluation and therapeutic approach
to the child or adolescent with hypertension should take
into account the particular clinical situation of the patient,
as illustrated in the case discussions.
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Questions (answers appear after References)
1. Recently issued recommendations for staging hyper-
tension in children and adolescents provide guidance
for clinicians in evaluating patients with elevated
blood pressure. The new staging system recom-
mends immediate institution of antihypertensive
medications for patients with BP in which of the
following stages:
(a) Stage 2 hypertension
(b) Normal blood pressure
(c) Stage 1 hypertension
(d) Pre-hypertension
2. Diuretics should always be used in the treatment of
athletes with hypertension because of the frequency of
high-salt diets in young athletes.
(a) True
(b) False
3. Renal insufficiency and proteinuria are common in
children with CKD, even those with non-glomerular
diseases. When these are present, which of the
following drug classes should be considered as appro-
priate therapy?
(a) Dihydropyridine calcium channel blockers
(b) Angiotensin receptor antagonists
(c) Centrally acting agents
(d) Beta-adrenergic blockers
4. The NHBPEP Working Group recommends that chil-
dren with renal disease have a target blood pressure
<90th percentile for age, gender, and height and that
ACE inhibitors or ARBs be used preferentially for
children with proteinuric renal disease.
(a) True
(b) False
5. A 16-year-old obese boy with hypertension and type 2
diabetes has been referred to you for evaluation. His
office BP is 145/82 mmHg. An echocardiogram
indicates that has LVH, and he has a mildly elevated
urinary microalbumin to creatinine ratio. The referring
physician prescribed hydrochlorothiazide 50 mg daily.
Your recommendation should be:
(a) Order ambulatory BP monitoring to assess his
blood pressure control
(b) Add metoprolol 100 mg daily to reduce his blood
pressure further
(c) Start him on regular aerobic exercise and a low-
sodium diet
(d) Stop the hydrochlorothiazide and start lisinopril
10 mg daily
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